Eudemus Pharmaceuticals

Eudemus Pharmaceuticals is a precision biotechnology company focused on developing transformative therapies for Huntington's disease (HD). Founded by Dr. Michael Hayden, a world-renowned geneticist and pioneer in HD research, the company aims to address the underlying genetic cause of the condition. Eudemus is specifically advancing small molecule candidates designed to lower the levels of mutant huntingtin protein (mHTT), which is the primary driver of neurodegeneration in patients. By leveraging deep expertise in genetics and drug discovery, the company seeks to provide disease-modifying treatments that can slow or halt disease progression. Currently in the pre-clinical stage, Eudemus represents a new venture in the neurology space following the founder's successful track record with companies like Xenon Pharmaceuticals and Prilenia Therapeutics.